Introduction
Fanconi Anemia (FA) is a recessive congenital disorder clinically characterized by bone marrow failure, congenital malformations, endocrine disfunction and an extraordinary high predisposition to neoplasias. Patients develop a progressive thrombocytopenia and eventually pancytopenia during the first decade of their life that can be treated with androgens but in most cases require an hematopoietic stem cell (HSC) transplantation under specific protocols adapted to their characteristics. Although great advances have been achieved, the drugs used sometimes have undesirable side effects, and is not always possible to find a related donor for the transplantation, leading to severe complications. A better understanding of the molecular basis of bone marrow failure in these patients will help in the development of new treatments.
To date, fifteen different genes have been involved in the development of FA, designated as FANC genes. The assimilation of some of these FANC gene products with previously known proteins involved in DNA repair pathways led to the discovery of their participation in nuclear complexes involved in the resolution of DNA interstrand crosslinks generated during the normal physiology of the cell or induced by certain drugs (1) . In addition to their participation in the FA-BRCA nuclear DNA repair complex, certain FANC proteins have been involved in signaling pathways that shed light into other aspects of the FA phenotype like the endocrine disfunction or the sensitivity to inflammatory cytokines (2, 3) . Moreover, the combination of the sensitivity of FA progenitor hematopoietic cells to inflammatory cytokines with the elevated production of IFNγ, TNFα and IL-1ß in these patients is thought to contribute to their bone marrow failure and posterior malignization (4) (5) (6) . Thus, two different mechanisms are nowadays considered to participate in the bone marrow failure of FA patients: On one hand, FA cells accumulate DNA damage in each division that results in an exacerbated p53 activation and apoptosis of their hematopoietic progenitors (7) , on the other, FA patients overproduce inhibitory cytokines, that eventually degrades their bone marrow (8) .
Signal transducers and activators of transcription (STAT) are transcription factors activated by phosphorylation triggered by ligand-bound cell surface receptors. STAT factors mediate signaling initiated by many extracellular stimuli including cytokines and growth factors and induce responses like cell proliferation, differentiation and apoptosis (9) . STAT1 is phosphorylated at tyrosine 701 in response to IFNγ activation and then is translocated to the nucleus where it promotes the transcription of specific genes. Interestingly, FANCC was demonstrated to interact with and be necessary for the correct activation of STAT1 in response to interferon gamma (IFNγ) (10) . The importance of STAT1 in IFNγ signaling comes from studies with mutant cell lines and mice. STAT1 knockout mice show high susceptibility to microbial and viral infections as well as tumor formation due to the abrogation in the induction of certain target genes (11, 12) . Recently, STAT1 has also been involved in the induction of apoptosis in response to DNA damage (13) (14) (15) , a process regulated by its interaction with p53 (16).
Here we report an elevation in STAT1 levels in FANCA-deficient cells that condition a stronger activation of the pathway in these cells, and may mediate the depletion of hematopoietic progenitor cells in the patients. We demonstrate that STAT1 also participates in the sensitivity of FA-A lymphoblastoid cell lines (LCLs) to DNA interstrand crosslinking agents. This discovery provides an explanation to the sensitivity of FA-A cells to both genotoxic and inflammatory stresses, and suggest the use of STAT1 inhibitors as potential protectors of hematopoiesis in FA-A patients. CACACGCTCCCAGGCGAAGTC) and ß2 microglobulin (ß2µ) (5ʼ-GAGACATGTAAGCAGCATCA and 5ʼ-AGCAACCTGCTCAGATACAT). After 30 amplification cycles, except for ß2µ (25), the expected PCR products were sizefractionated onto a 2% agarose gel and stained with ethidium bromide. For the quantitative analysis, the normalized expression values of triplicates against a housekeeping gene were graphed.
RNA Interference assays
To genetically block the expression of STAT1 in LCLs, we transduced a shRNA contruct against STAT1 (reference TRCN0000280024 from Sigma, St. Louis, USA) into the cells and selected the transduced cells by cell sorting. The efficacy in STAT1 blockade was tested by the analysis of its mRNA expression according to the manufacturerʼs instructions.
Western blot analysis
To prepare whole cell lysates, cells were collected by centrifugation and washed once with PBS and then lysed in EBC buffer (50mM Tris [pH 8.0], 120 mM NaCl, 0.5% Nonidet P-40) supplemented with aprotinin (11.5 µg/ml), leupeptin (11.5 µg/ml) phenylmethylsulfonyl fluoride (50 µg/ml), NaF (100mM) and Na Ortovanadate (0.2 mM). Protein concentration was determined by BCA following the manufacturerʼs instructions (Pierce, Rockford, USA). Proteins (100 µg) were resolved in SDS-PAGE and transferred to PVDF filters. Blots were incubated with rabbit antibodies against P-Tyr-STAT1, P-ERK, ERK2, PARP or GAPDH (Santa Cruz, Santa Cruz, USA) and then incubated with goat anti-rabbit or anti-mouse antibodies conjugated with horseradish peroxidase (Pierce, Rockford, USA). Bound antibody was detected by a chemiluminescence assay (Pierce, Rockford, USA).
Gene reporter assay
A genomic PCR fragment of 628 base pairs (bp) (-588 to +40, referred to the initiation of transcription) from the 5ʼ regulatory region of STAT1 was amplified using specific primers and cloned into the pGL2basic luciferase reporter vector (Promega, Madison, USA). 293T cells were cotransfected with 2 µg pGL2-STAT1-588/+40 construct, 1µg of a expression vector for hRasV12-S35 and 0,2 µg pRSV-ß-gal in triplicate using Superfect (Qiagen, Düsseldorf, Germany) according to the manufacturerʼs directions. 36 hours after transfection, cell extracts were prepared and analyzed for their luciferase activity by using a reporter gene assay system (Promega, Madison, USA). Results were normalized for transfection efficiency with the ß-galactosidase activity values obtained in the same extracts.
Results

STAT1 is overpressed in FA-A LCL
Our previous results led us to test the functionality of the STAT1 pathway in FA-A LCLs. Data from Pang et al. demonstrated an altered function of the JAK-STAT pathway in FANCC-deficient cells (10, 17) . Surprisingly, we discovered that the STAT1 protein was overexpressed in lymphoblastoid cell lines (LCLs) derived from FA-A patients compared to those derived from healthy donors ( figure 1A) . In order to confirm that STAT1 overproduction was only due to the lack of a functional FANCA protein in these cells, we transduced a wild type FANCA cDNA into FA-A LCLs that corrected their phenotype. By western blot, we could confirm a reduction on the levels of STAT1 protein in FA-A corrected cells of two different cell lines (figure 1B), demonstrating the involvement of FANCA in the expression of this protein. Interestingly, we observed no variation in the level of STAT1 protein in FANCC-deficient cells compared to their isogenic corrected counterparts (figure 1C), suggesting a specific role of FANCA protein in the modulation of STAT1 expression. We next wanted to confirm that the results obtained in our lymphoblastoid cell lines are a reflex of what happens in the patients and not a consequence of the immortalization process. To this end, we analyzed the amount of STAT1 protein in extracts from bone marrow primary samples. As seen in figure 1D , STAT1 protein accumulates at a higher level in the samples analyzed.
We also investigated whether the accumulation of the STAT1 transcription factor is paralleled by an accumulation of its messenger RNA. A roughly 2 fold increase in STAT1 mRNA expression was observed in FA-A LCLs compared to LCLs derived from healthy donors ( figure 1E ). To verify the involvement of FANCA disfunction in this observation, two different FA-A lymphoblastoid cell lines were analyzed by quantitative RT-PCR and compared to their respective phenotypically corrected counterparts. We observed a two fold increase in STAT1 mRNA accumulation in FA-A LCLs ( figure 1G ). No increase, or even a decrease, was observed in FANCC-deficient cells compared to their FANCC-transduced counterparts (figure 1I). We also analyzed the expression of the mRNAs coding for the isoforms alpha and beta of STAT1. The mRNA for both isoforms were overexpressed in FANCA-deficient LCLs compared either to healthyderived LCLs or to their isogenic corrected cell lines transduced with a wild type FANCA cDNA ( figure 1E and 1H ). Other members of the STAT family showed no basal overexpression in FANCA-deficient cells when compared to their FANCA-transduced counterparts ( figure 1H ). Finally, we analyzed the expression of STAT1 mRNA in primary mononuclear cells from peripheral blood samples of FA-A patients. Overall, STAT1 showed a higher mRNA expression in the samples of the patients than in the samples obtained from healthy donors ( figure 1F ).
All these data demonstrate that the lack of a functional FANCA protein leads to overexpression of STAT1 protein in FA patients.
STAT1 protein accumulation in FA-A LCL obeys to transcriptional and postranslational mechanisms
In order to discard a putative mRNA stabilization mechanism in the accumulation of STAT1 mRNA in FA-A cells, we studied its degradation after blocking general transcription with actinomycin D. STAT1 mRNA has a half life of about 12 hours in LCLs, but the profile of its decay was similar in FA-A and control cells (figure 2A), suggesting that STAT1 mRNA overexpression has a transcriptional basis in FANCAdeficient cells. However, the low differences at the mRNA level do not perfectly correlate with the strong induction of the STAT1 protein in FA-A LCLs (compare figures 1A and 1E), so we suspected that postranslational mechanisms could be contributing to STAT1 protein accumulation. To support this idea, we studied STAT1 protein half life in FA-A LCLs. After cyclohexymide treatment, STAT1 protein maintain its level for about 3 hours in FANCA-proficient cells, with a profound decay between 3 and 17 hours (figure 2B). In contrast, FA-A LCLs still maintain high levels of STAT1 protein after 17 hours of cyclohexymide treatment, indicating an alteration in the renewal mechanism of this protein in FANCA-deficient cells. Together, these results demonstrate that FANCA deficiency leads to an increased transcription of the STAT1 gene and a stabilization of the STAT1 factor.
FANCA-deficient cells phosphorylate STAT1 normally in response to IFNγ
FANCC protein has been reported to be necessary for the correct activation of STAT1 in response to interferon gamma (IFNγ) (10) . We wanted to know if STAT1 is correctly activated in FANCA-deficient cells. We analyzed the accumulation of tyrosine 701-phosphorylated STAT1 in FA-A LCLs after treatment with IFNγ by western blot using a specific antibody. Our results showed that STAT1 is not only phosphorylated normally in FANCA-deficient cells but the levels of Tyr701-P-STAT1 raise much higher in response to IFNγ, probably due to the elevated levels of the STAT1 protein in these cells ( figure  3A ). When we performed a time course of this phosphorylation in LCLs, we observed a rapid increase in Tyr701-P-STAT1 that peaks at about 30 minutes and then returns to normal levels about 2 hours after treatment. This profile of induction was essentially identical in FA-A LCLs, although the amount of Tyr701-P-STAT1 raised to a much higher level ( figure 3B ).
These data demonstrate that tyrosine phosphorylation of STAT1 in response to IFNγ is not defective in FANCA-deficient LCLs and suggest that the high STAT1 levels in FANCA-deficient hematopoietic progenitor cells would generate an exaggerated response to the high levels of IFNγ produced by FA patients, contributing to their bone marrow failure.
Lymphoblastoid cell lines do not respond to IFNγ or TNFα
It has been reported that the hypersensitivity of the FA hematopoietic stem cells to inhibitory cytokines like IFNγ and TNFα, overproduced by FA patients, may be related to their progressive bone marrow failure (4, 18, 19) . The fact that STAT1 is phosphorylated in response to IFNγ demonstrates the presence of functional receptors for this cytokine in FA-A LCLs (figures 3A and 3B). Interestingly, although IFNγ induced the binding of STAT1 to a consensus binding site both in FA-A LCLs and their corrected counterparts in an EMSA, no difference between them was detected (data not shown).
In an attempt to correlate the overexpresion of STAT1 with a stronger response of FA-A hematopoietic progenitors to IFNγ, we used our LCL model to analyzed the basal and IFNγ-induced expression of a group of genes known to respond to this cytokine. Thus, we treated FA-A LCLs with increasing concentrations of IFNγ and studied their mRNA expression by quantitative RT-PCR. Some of the genes tested, like MX1 and CISH, show higher basal expression in FA-A cells than in their corrected counterparts. Others show very little or no differences in their basal mRNA expression. However, for all of these genes, IFNγ is not inducing any change in their expression ( figure 3C ). In spite of these results, we tested if LCLs could reproduce the sensibility of FANCA-deficient hematopoietic progenitors to inhibitory cytokines. However, the viability of LCLs did not show any change in response to increasing doses of IFNγ, TNFα or the combination of both, independently of their FANCA status ( figure 3D ). Altogether, this group of results suggests that although STAT1 is normally phosphorylated in tyrosine 701, its function in IFNγ signaling is abrogated in lymphoblastoid cell lines, probably as part of the immortalization process by EpsteinBarr virus.
STAT1 overexpression plays a role in the sensitivity of FA-A LCL to interstrand DNA crosslinking agents Accumulating evidence gives STAT1 a key role in various forms of cell death (15) . It is well known that FANCA-deficient cells are very sensitive to DNA crosslinking drugs. We used a XTT assay to confirm the decrease in cell viability of our FA LCLs at doses of cisplatin lower than for their corrected counterparts (figure 4A). In order to establish a role of STAT1 in this hypersensitivity, we interfered STAT1 expression by transfecting a small-hairpin RNA (shRNA) specific for this gene into FA-A LCLs. This construct was able to reduce STAT1 mRNA expression in about 50% (figure 4B). Cells transduced with this construct normalize their sensitivity to cisplatin, as measured by the number of PI+ cells under these conditions (figure 4C), or using a viability XTT assay ( figure 4D ). Epigallocatechin-3-gallate (EGCG) is a compound with STAT1-inhibiting activity that is capable to protect cells from apoptosis (20, 21) . Thus, we decided to use it in our FA-A LCLs to analyze its effect over the characteristic sensitivity of these cells to interstrand DNA crosslinking agents. First, we studied its effect on STAT1. We found that EGCG reverts STAT1 mRNA levels to those observed in corrected LCLs (figure 4E). This effect seems specific among other members of the STAT family (figure 4E). When we treated FA-A LCLs with EGCG and increasing doses of cisplatin to test its effect on their viability, cells become more resistant to cisplatin in a EGCG dose-dependent manner ( figure 4F ). These data demonstrate a key role of STAT1 overexpression in FA-A LCL sensitivity to interstrand DNA crosslinking agents.
The activation of ERK in FA-A cells is responsible of the STAT1 accumulation in these cells
Several groups have reported a constitutive activation of ERK in FANCA-deficient cells (22) . In addition, we observed that the stimulation of FA-A LCLs with MMC induces a temporary increase in the phosphorylation of ERK, stronger in FANCA-deficient cells (figure 5A), suggesting a role of this kinase in the MMC-sensitive phenotype of these cells as determined by the persistency of digested PARP in them. Since our data support a role of STAT1 in the sensitivity of FANCA-deficient cells to DNA interstrand crosslinking agents, we wondered if the activation of ERK in FA-A cells might be modulating the levels of STAT1. We treated FA-A LCLs with increasing doses of U0126, an inhibitor of the activation of ERK, and observed a progressive reduction in the amount of both STAT1 factor and its messenger (figures 5B and 5C). In addition, a region of the sequence upstream of the transcriptional start site of the gene is activated when cotransfected with RasV12-S35, a mutant of Ras that specifically activates the Raf pathway ( figure 5D ). These results demonstrate that the constitutive activation of ERK increases the expression of STAT1 in FA-A LCLs. We then asked whether the reduction in STAT1 induced by the inhibition of ERK is able to affect the sensitivity of FA-A LCLs to cisplatin, an ICL-generating drug. Treatment with U0126 improved the viability of FA-A LCLs in response to cisplatin, in contrast with the treatment with SB203580, an inhibitor of p38, that showed no effect (figure 5E). These data further confirm a key role of STAT1 in the sensitivity of FA-A LCLs to ICLgenerating agents and reveal ERK as a modulator of its expression in these cells.
Discussion
One of the most important clinical manifestations of Fanconi Anemia (FA) is its progressive bone marrow failure that threatens the life of the patients in the first decade of their life. The nowadays accepted idea is that the depletion of hematopoietic stem cells is a consequence of the failure of the DNA repair mechanisms in FA cells that exacerbates the apoptosis mechanisms (7). However, FA cells are also prone to apoptosis induced by inflammatory cytokines that, on the other hand, are aberrantly overproduced in these patients (6, 18) . Increasing evidences are now supporting the importance of this inhibitory cytokines in the bone marrow failure of FA patients. Indeed, a recent study was aimed to find inhibitory molecules to reduce the production of TNFα in FA patients that may retard their progressive bone marrow failure (8) . In the present article, we provide evidence of an overexpression of STAT1 in FANCA-deficient cells and how this may explain at the same time the hypersensitivity of FA-A cells to genotoxic agents and to inflammatory cytokines. Most of the studies dealing with the sensitivity of FA cells to inflammatory cytokines have been carried out on FA-C lymphoblastoid cells lines (LCLs). This model allowed the discovery that the protein FANCC directly interacts with STAT1 facilitating its activation in response to IFNγ (10, 23) . Here, we report a higher accumulation of STAT1 and its messenger in FA-A LCLs when compared to LCLs derived from healthy donors. Although we could confirm this observation in a group of LCLs derived from different FA-A patients, in order to discard a possible differential influence of the immortalization process in STAT1 overexpression, we used as controls for the FA-A cell lines isogenic counterparts where the FANCA gene was either spontaneously reverted or introduced in its wild type form using a viral vector. FANCA function restoration, demonstrated by reversion of the hypersensitivity to interstrand DNA crosslinking agents (figure 4A), reduced STAT1 protein and mRNA levels in FA-A LCLs. We analyzed the stability of the mRNA and the protein of STAT1 to get some insight into the mechanism by which the lack of a functional FANCA protein leads to an induction of STAT1 expression. Our data suggest this mechanism is complex, involving a regulation of STAT1 gene transcription and a stabilization of the STAT1 protein. This agrees with data from other groups reporting both types of STAT1 regulation in AML cell lines (24) . The overexpression of STAT1 in FA-A cells suggests it may contribute to the hypersensitivity of FA-A hematopoietic stem cells to cytotoxic cytokines. Hypersensitivity to inhibitory cytokines is a characteristic of FA hematopoietic stem cells, reported to be reproduced by FA-C LCLs (25). However, FA-A LCLs do not show any viability variation in response to IFNγ, TNFα or a combination of both at doses as high as 50 ng/ml each ( figure 3D ). This result is in agreement with the observation of Pang et al. that reported that, in contrast to FA-C fibroblasts, FA-A and FA-G fibroblasts exhibit no more sensitivity to IFNγ and dsRNA treatment than normal fibroblasts (26). Surprisingly, STAT1 phosphorylation in tyrosine 701 proceeds normally in FA-A LCLs (figure 3A and 3B), in deep contrast to what has been reported for FA-C LCLs (10) . Due to the overexpression of STAT1, IFNγ induces much higher levels of tyrosine-phosphorylated STAT1 in FA-A LCLs. However, the pathway is defective as this stronger activation is not translated into a higher DNA binding activity of STAT1 (data not shown) or higher expression of IFNγ-induced genes (figure 3C), although some of them like MX1 or CISH1 show higher basal levels in FA-A LCLs. These results agree with previous observations done in FANCC-deficient cells (23, 27) . In this respect, FA-A and FA-C LCLs share this common failure in the induction of IFNγ responsive genes and also the fact that some of them show higher basal levels in FA cells. However, while FANCCdeficient cells fail in the activation of STAT1 by IFNγ, our data suggest that FANCAdeficient cells bear a failure in the STAT1 transactivation functions. These results support the idea that FANC proteins have other functions away from their participation in nuclear DNA repair protein complexes and provide a molecular basis for FANCA and FANCC phenotypic differences. The impairment in the response of this pathway, considered as an anti-viral pathway, could also be attributable to the interference of the Epstein-Barr virus used in the immortalization process to generate the lymphoblastoid cell lines. This idea is supported by the fact that no LCLs showed variations in their viability in response to cytokines, independently of their FANC protein status. Given that the most clear biological characteristic of the FA-A LCLs is their higher sensitivity to DNA interstrand crosslinking agents (figure 4A), we decided to investigate the role of STAT1 overexpression in this aberrant response. Many different observations have attributed STAT1 a function in the inhibition of cell growth and the promotion of apoptosis (15, 28 ). Our data demonstrate that the STAT1 elevated levels in FA-A lymphoblasts directly correlate with their sensitivity to cisplatin. These data are in agreement with previous works reporting that STAT1 interacts with and acts as a coactivator of p53 in the DNA damage induction of apoptosis (13) . Moreover, preliminary results from our lab indicate that interference of STAT1 expression using shRNA constructs impairs the accumulation of p53 after cisplatin treatment in FA-A LCLs. This exacerbated p53 response to DNA damage has been demonstrated to reduce the hematopoietic stem cell pool in FA patients (7) and our data support a role of STAT1 in this process, maybe through the inhibition of MDM2 (13) . Importantly, we describe a chemical inhibitor of STAT1, epigallocatechin-3-gallate, that improves the viability of both FANCA-deficient and -proficient LCLs in the presence of DNA interstrand crosslinking drugs (figure 4). This opens a new therapeutical way to treat the progressive bone marrow failure of FA patients. Although epigallocatechin-3-gallate has been reported to show specificity in the inhibition of STAT1 (20) , the spectrum of described effects of this compound within the cell is quite broad and include the prevention of oxidative damage, antiangiogenic, antitumoral and modulator of cell response to chemotherapy (29). All of these effects indicate epigallocatechin-3-gallate as a great drug in the treatment of Fanconi Anemia, although further studies are needed to establish its actual effects on FA cells. One of the molecular characteristics of FANCA-deficient cells is their constitutive activation of several MAPK pathways (22) . However, our previous data demonstrated a failure to correctly activate JNK in response to genotoxic stress in FA-A LCLs (30). Moreover, a screen of activated kinases in FA cells performed in our laboratory showed elevated levels of phosphorylated ERK and p38 but not significant variations in JNK activation in FANCA-deficient LCLs (unpublished results). This led us to hypothesize a regulation of STAT1 by ERK in FA-A cells. It has been previously reported a role of the ERK pathway in the accumulation and activation of STAT1 in myeloid leukemia cell lines (24) . We obtained evidence of such regulation by cotransfecting a luciferase reporter construct driven by a regulatory region of the STAT1 gene along with an expression vector for RasV12-S35, a mutant of Ras that specifically activates the Raf-ERK pathway (31). Our data confirm the constitutive activation of ERK in FA-A LCLs and how its inhibition leads to a reduction on both STAT1 messenger and its coded protein. Moreover, treatment of FA-A LCLs with U0126, an inhibitor of ERK activation, has a similar cisplatin-protecting effect as EGCG, further underlining the role of STAT1 overexpression on their sensitivity to cisplatin and opening different ways to block its effect. In summary, we report here a STAT1 overexpression in FANCA-deficient cells due to the constitutive activation of ERK in these cells, that provide an explanation to the mixed sensitivity of FA cells to genotoxic stress and to inhibitory cytokines. Most importantly, we report the action of two compounds that revert this sensitivity. peripheral blood samples. We also thank Rosario Gaitán for the management of the deliveries. FA lymphoblastoid cells lines and their corrected counterparts were kindly provided by doctors Juan Bueren from Ciemat, Madrid and Jordi Surrallés from UAB, Barcelona. 
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